Trial Profile
Golimumab in Seropositive and Seronegative Rheumatoid Arthritis Patients in Real-Life Settings and Clinical Outcomes -Data from Italian Register Gisea
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Jul 2018
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 15 Jul 2018 New trial record
- 16 Jun 2018 Results assessing clinical outcomes of treatment with Golimumab, presented at the 19th Annual Congress of the European League Against Rheumatism